BRA
ASMB icon

Blue Rock Advisors’s Assembly Biosciences ASMB Stock Holding History

Blue Rock Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,225
Closed -$242K – 36
2020
Q3 		$242K Buy
+1,225
New +$308K 0.21% 79

Other funds holding ASMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Blue Rock Advisors's ASMB Position: Q4 2020 in Review

Blue Rock Advisors sold out of Assembly Biosciences (ASMB) in Q4 2020, closing a stake of 1,225 shares — an estimated $242K sold.

Blue Rock Advisors first reported a position in ASMB in Q3 2020 and held it in 1 quarter. The position peaked at $242K in Q3 2020. 109 funds tracked by Wall St. Rank hold ASMB as of Q4 2020.

  • Blue Rock Advisors reported no remaining Assembly Biosciences position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 1,225 Assembly Biosciences shares in Q4 2020, an estimated $242K.
  • Blue Rock Advisors first reported a position in Assembly Biosciences in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's Assembly Biosciences position peaked at $242K in Q3 2020.
  • 109 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.